Y10S 424/801
Involving antibody or fragment thereof produced by recombinant dna technology
Official title: involving antibody or fragment thereof produced by recombinant dna technology
Y10S424/801 (Involving antibody or fragment thereof produced by recombinant dna technology) appears on 56 US grants and 48 published applications in this corpus.
Search patents in Y10S- Granted patents
- 56
- Published applications
- 48
- Assignees
- 41
- Inventors
- 93
- Latest grant
- 3 Sep 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 5 | 2 |
| 2003 | 2 | 3 |
| 2004 | 3 | 1 |
| 2005 | 1 | 7 |
| 2006 | 2 | 5 |
| 2007 | 0 | 1 |
| 2008 | 4 | 2 |
| 2009 | 6 | 0 |
| 2010 | 1 | 4 |
| 2011 | 4 | 6 |
| 2012 | 4 | 3 |
| 2013 | 3 | 4 |
| 2014 | 2 | 5 |
| 2015 | 2 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Treatment of diffuse large-cell lymphoma with anti-CD20 antibody3 Sep 2019US 10,400,043 B2Biogen, Inc.
- Treatment of pemphigus12 Jun 2018US 9,993,550 B2Biogen Idec Inc.
- Treatment of diffuse large-cell lymphoma with anti-CD20 antibody29 Nov 2016US 9,504,744 B2Biogen, Inc.
- Agonist antibody to human thrombopoietin receptor7 Apr 2015US 8,999,329 B2Kyowa Hakko Kirin Co., Ltd.
- Anti-ανβ6 antibodies and uses thereof31 Mar 2015US 8,992,924 B2Biogen Idec MA Inc.
- Treatment of autoimmune diseases20 Sep 2018US 2018/0264107 A1Biogen, Inc.
- Treatment of diffuse large-cell lymphoma with anti-cd20 antibody3 May 2018US 2018/0118844 A1Biogen, Inc.
- Treatment of diffuse large-cell lymphoma with anti-cd20 antibody9 Feb 2017US 2017/0037139 A1Biogen, Inc.
- Treatment of pemphigus23 Jun 2016US 2016/0175435 A1Biogen, Inc.
- Avian Derived Antibodies13 Nov 2014US 2014/0336362 A1Synageva BioPharma Corp.
Most cited
By later US patents
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998
- Biosynthetic antibody binding sites393US 5,132,405 ACreative BioMolecules, Inc. · 1992
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma287US 5,776,456 AIDEC Pharmaceuticals Corporation · 1998
- Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies166US 6,949,245 B1Genentech, Inc. · 2005
- Recombinant antibodies and methods for their production in which surface residues are altered to cysteine residues for attachment of effector or receptor molecules153US 5,219,996 ACelltech Limited · 1993